A1 Refereed original research article in a scientific journal

Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial




AuthorsPirkko-Liisa Kellokumpu-Lehtinen, Timo Marttila, Antti Jekunen, Petteri Hervonen, Katariina Klintrup, Vesa Kataja, Tapio Utriainen, Marjaana Luukkaa, Markku Leskinen, Kalevi Pulkkanen, Anna-Liisa Kautio, Teppo Huttunen

PublisherINT INST ANTICANCER RESEARCH

Publication year2020

JournalAnticancer Research

Journal name in sourceANTICANCER RESEARCH

Journal acronymANTICANCER RES

Volume40

Issue12

First page 6915

Last page6921

Number of pages7

ISSN0250-7005

eISSN1791-7530

DOIhttps://doi.org/10.21873/anticanres.14715(external)

Web address https://ar.iiarjournals.org/content/40/12/6915(external)


Abstract
Background/Aim: Our phase III trial showed that biweekly docetaxel (D) is better tolerated than triweekly D in metastatic castration-resistant prostate cancer (mCRPC). The safety of biweekly cabazitaxel (CBZ) post-docetaxel was studied in mCRPC. Patients and Methods: Altogether, 60 patients received CBZ 16 mg/m2 i.v. on day 1 and day 14 of a 4-week cycle. The mean serum PSA levels were 305 ng/ml, and the mean age 67 years. The primary endpoint was safety according to CTCAEv4.0. Results: A total of 255 4-week cycles of CBZ were administered. The most common grade 3/4 adverse events were neutropenia (16.7%), pain (13.3%), fatigue (10.0%), anemia (5.0%) and non-neutropenic infection (10.0%). PSA responses occurred in 10 patients (16.7%). Clinical benefit rate was 38.3% and median survival 10 months. Conclusion: Biweekly CBZ is a well-tolerated treatment resulting in meaningful benefits for heavily pretreated mCRPC patients.



Last updated on 2024-26-11 at 18:03